Physician profile
Raymond E Pontzer
NPI 1144262031
$1,622.21
in general payments reported to CMS, 2019-2025
11 companies · $67.28 in 2025
The $67.28 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $93.01 · 2021: $145 · 2022: $127 · 2023: $520 · 2024: $199 · 2025: $67.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $497.03 | 2019-2025 | Vibativ |
| Merck Sharp & Dohme LLC | $326.02 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $206.19 | 2022-2024 | |
| Insmed, INC. | $192.14 | 2019-2024 | Arikayce |
| Paratek Pharmaceuticals, INC. | $157.14 | 2019-2023 | Nuzyra |
| Janssen Pharmaceuticals, INC | $80.66 | 2019 | |
| Melinta Therapeutics, LLC | $61.70 | 2020-2023 | Orbactiv, Kimyrsa, Rezzayo |
| Tetraphase Pharmaceuticals, INC. | $44.93 | 2019 | |
| Aimmune Therapeutics, INC. | $24.15 | 2025 | Vowst |
| Astellas Pharma US INC | $17.80 | 2024 | Cresemba |
| Ferring Pharmaceuticals INC. | $14.45 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Pontzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.